Schizophrenia

Schizophrenia is a chronic psychiatric disorder that affects how a person perceives reality, thinks, feels, and behaves. Its best-known features are psychosis, including delusions and hallucinations, but it also involves reduced emotional expression, low motivation, and impaired cognition. Symptoms usually first appear in late adolescence or early adulthood. Because the condition often disrupts education, work, and close relationships, it is one of the most socially consequential of all mental illnesses.

The concept has changed considerably since it was first described in the late nineteenth century. Its causes are still not fully understood, and current research treats it as the product of genetic susceptibility, early brain development, and environmental influences acting together, rather than a single cause. Treatment has improved with antipsychotic medicines, psychosocial interventions, and specialized early-intervention services, and a new drug with a non-dopamine mechanism was approved in 2024. Outcomes still vary widely, and many people face lasting difficulties, shorter life expectancy, and stigma.

This entry traces how the disorder is named and defined, describes its clinical features and diagnostic criteria, and summarizes its course, prevalence, and risk factors. It then reviews the genetic, neurodevelopmental, and neurochemical research behind it, followed by pharmacological and psychosocial treatment. It closes with physical comorbidity and social consequences, and with the unresolved debates about diagnosis, mechanism, and care.

Naming and the Shaping of the Concept

Kraepelin and dementia praecox

Before the modern name existed, clinicians grouped chronic, early-onset psychotic illness under several labels. The German psychiatrist Emil Kraepelin gave this group its first systematic shape. The Kraepelinian dichotomy divided the major endogenous psychoses into dementia praecox and manic-depressive psychosis. This division was formally introduced in the sixth edition of Kraepelin's psychiatric textbook Psychiatrie, published in 1899. Kraepelin separated the two conditions mainly by course. Dementia praecox was, in his account, a process that ended in progressive deterioration from which no one recovered, while the mood illness he called manic-depressive insanity was episodic, with recovery between episodes, and is now largely conceived as bipolar disorder. He also noted that age of onset, family history and premorbid personality or temperament were useful in distinguishing the two.

Later historians have qualified this picture. Kraepelin's clinical sample consisted largely of patients with long inpatient stays, which likely led him to overestimate the progressive decline in dementia praecox. By 1913, and more explicitly by 1920, he admitted that while there may be a residual cognitive defect in most cases, the prognosis was not as uniformly dire as he had stated in the 1890s.

Bleuler and the term schizophrenia

The Swiss psychiatrist Eugen Bleuler introduced the replacement term. He and his colleagues had been using the term in Zurich to replace Kraepelin's term dementia praecox since 1907. The name entered the literature on 24 April 1908, when Bleuler presented his paper on the prognosis of the dementia praecox group at the German Psychiatric Association meeting. He expanded the concept in a 1911 monograph. The word was meant to describe a loosening or splitting of psychological functions, but it was soon misread as a "split personality," a misunderstanding that Bleuler's own work did not support. Bleuler put the incoherence of cognitive and affective functioning in the foreground, rather than the course of the disease. He also noted that not all patients had a progressive decline, a perspective that broadened the diagnosis from Kraepelin's original formulation. Historians still disagree about his legacy. One reading holds that Bleuler merely renamed 'dementia praecox' while conceptually continuing the Kraepelinian tradition. The other accredits him with a genuine re-conceptualization. Bleuler also distinguished positive from negative symptoms, describing the absence of typical experiences such as social withdrawal or lack of pleasure as negative.

Schneider and first-rank symptoms

The most influential diagnostic innovation of the mid-twentieth century came from Kurt Schneider (1887–1967). The first formal proposal of Schneider's 'first-rank symptoms' was contained in a 1939 monograph he wrote on psychiatric diagnoses for general practitioners and 'interested psychiatrists.' An English description of these symptoms first appeared in the 1959 translation of his textbook, Clinical Psychopathology. Schneider's list of first-rank features included auditory hallucinations (audible thoughts, conversational voices, and voices commenting on one's actions), experiences of thought withdrawal, thought broadcasting, and thought insertion, and delusional perception. He ranked these above other features, such as hallucinations of other kinds or sustained delusional moods, which he considered less specific. His purpose was practical: they were meant to help a clinician recognize a condition in order to take action. Critics note that by focusing on these items he neglected what Emil Kraepelin and Eugen Bleuler had emphasized decades earlier and devised his own criteria, consisting exclusively of hallucinations and delusions.

From concept to criteria

The first-rank symptoms carried forward into the operational era. Through the incorporation of several first-rank symptoms into the psychosis section of the Present State Examination and from there into the schizophrenia section of the Research Diagnostic Criteria and the DSM-III, they substantially influenced diagnostic approaches to schizophrenia for several decades. In DSM-III, the thought disturbances were included as diagnostic criteria for schizophrenia and described as 'characteristic delusions.' This wording generated lasting debate over whether these experiences are best treated as primary subjective symptoms or as false beliefs. The change also reflected a wider problem. Before the 1970s, clinicians in different countries used overlapping but unequal definitions, and the WHO International Pilot Study of Schizophrenia at the turn of the 1970s helped expose how much those definitions differed. The response was to replace broad clinical judgment about course, personality and symptom pattern with explicit checklists, a move visible in the Research Diagnostic Criteria and the 1980 DSM-III. Those criteria are discussed in the diagnosis sections below.

Clinical Features

Positive symptoms

Positive symptoms are experiences or behaviors that are added to a person's functioning, as opposed to those that are lost. Delusions are false beliefs that significantly hinder a person's ability to function. A common form is persecutory: a person may be convinced that others mean them harm despite no supporting evidence, while other delusions involve a conviction of being someone else . Hallucinations are false perceptions that can occur in any sense. Auditory hallucinations are the most typical, and they are usually experienced as voices. These voices may comment on the person's actions, argue with each other, or issue instructions. Visual, tactile, and olfactory hallucinations occur less often.

Disorganized thought and speech is a separate positive domain. In speech it can appear as frequent derailment or incoherence, with the speaker jumping between unrelated topics or producing sentences that do not connect logically. Grossly disorganized behavior can include unpredictable agitation, odd dress, or neglect of self-care.

Negative symptoms

Negative symptoms are described as symptoms that appear to express a loss or diminution of normal function. The main components are diminished emotional expression (blunted or flat affect, with little facial or vocal expression), avolition (reduced initiative and goal-directed activity), alogia (poverty of speech), and anhedonia (reduced capacity for pleasure). Research has grouped these into two subdomains, amotivation (i.e., avolition/apathy and asociality) and diminished expression (i.e., poverty of speech and affective flattening).

They are hard to measure because they consist of absences, and ratings depend heavily on observers and on how a person behaves in a given setting. They also overlap with other conditions. Depression, sedation or motor side effects from antipsychotics, substance use, and social isolation can all produce similar presentations. Clinicians therefore try to separate primary negative symptoms, which are regarded as an integral dimension of schizophrenia, and secondary negative symptoms. If the two are confused, the result can be a false impression of worsening disease and an inappropriate escalation of dopamine-blocking medication . Negative symptoms matter largely because of their long-term effects. They significantly impair functional outcomes and quality of life, and they can persist after positive symptoms have been brought under control, which helps explain why many people remain unemployed or socially withdrawn.

Cognitive symptoms

Cognitive impairment is now considered a core feature rather than a side effect of the illness. Deficits are moderate to severe across several domains, including attention, working memory, verbal learning and memory, and executive functions. Processing speed, reasoning and problem solving, and social cognition are also commonly affected. Working memory, the ability to hold information in mind while acting on it, is among the most consistently reduced abilities. Everyday examples include following multistep instructions, retaining a new phone number, or doing mental arithmetic. Impaired working memory is linked to lower levels of activity in an area of the brain called the prefrontal cortex.

These deficits often appear before the first clear psychotic episode and tend to remain relatively stable across the course of illness. These deficits pre-date the onset of frank psychosis and are stable throughout the course of the illness in most patients. Because hallucinations and delusions are more dramatic, cognitive problems can be overlooked during acute episodes. A decline in school performance is sometimes the earliest visible sign in young people. Cognitive impairment is also tied closely to outcome: it is consistently the best predictor of functional outcomes across outcome domains and patient samples. Patients with more severe negative symptoms also tend to show greater deficits in working memory and executive function . Some recent studies suggest these deficits are malleable, which has encouraged the development of cognitive remediation programs.

Psychomotor and catatonic features

Disturbances of movement form another clinical domain. In chronic illness, Kraepelin described persistent, automatic, and bizarre movements such as mannerisms, stereotypies, grimacing, and perseveration. These are accompanied by withdrawal signs such as immobility, stupor, and mutism, and during acute episodes by agitated excitement . Catatonic features in the broader sense are movement and behavior changes including stupor, rigidity, echolalia (repeating others' words), and echopraxia (copying others' movements).

Catatonia is not specific to schizophrenia. While catatonic symptoms are not unique to schizophrenia and are neither necessary nor sufficient to diagnose it, abnormalities of psychomotor function are common in schizophrenia. Under DSM-5, catatonia is recognized as a specifier that can accompany several conditions. The older label of catatonic schizophrenia as a distinct subtype was eliminated as a separate diagnosis in 2013. Diagnosis requires at least three of a set of recognized signs, and mutism and stupor are the most common signs—each one present in over 90% of patients—and are considered the core criteria for the diagnosis. These figures come from catatonia studies rather than a general schizophrenia sample, so they should not be read as typical rates for all patients.

Presentation differs across people and across time. Some patients are largely immobile, while others show restlessness or agitation . In the same person, activity can swing between hypoactive and excessive states . Episodes may last minutes, hours, or days , and prolonged immobility can lead to serious medical complications, which is why catatonic states are treated as urgent.

Diagnosis and Classification

No laboratory test or brain scan confirms schizophrenia. Diagnosis depends on a longitudinal clinical history, a structured mental status examination, collateral information from family or other informants, and the exclusion of other causes. The two systems in general use are the American DSM-5-TR and the World Health Organization's ICD-11. They overlap heavily but differ in duration rules and in how they describe course.

Criteria in DSM-5-TR and ICD-11

In DSM-5-TR, the core requirement is two or more of five Criterion A symptoms: delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms. Each must be present for a significant portion of a one-month period, or for less time if treatment has already suppressed symptoms. At least one of the two must be a delusion, a hallucination, or disorganized speech, so negative symptoms cannot carry a diagnosis alone. Continuous signs of disturbance must last at least six months, and that span must include at least one month of active-phase symptoms; the rest may consist of prodromal or residual features such as blunted affect or mild, attenuated psychotic experiences. Two further conditions apply. Functioning in work, interpersonal relations, or self-care must be markedly below the level reached before onset. Schizoaffective disorder and mood disorders with psychotic features must be excluded, and so must the direct physiological effects of a substance or another medical condition. The older DSM subtypes (paranoid, disorganized, catatonic, and so on) were removed in DSM-5 because they had shown poor reliability and little predictive value. Episodes lasting one to six months fall under schizophreniform disorder instead.

ICD-11 places schizophrenia under the heading "schizophrenia or other primary psychotic disorders" with the code 6A20. It requires at least two characteristic symptoms, one of which should come from a core group: persistent delusions, persistent hallucinations, disorganized thinking, or experiences of influence, passivity, or control. These must be present most of the time for at least one month. ICD-11 has no separate six-month rule. Instead, it describes the illness with course specifiers (first episode, continuous, multiple episodes) and remission specifiers (partial or full), and it drops the former ICD-10 subtypes. Psychomotor disturbances, including catatonia, may accompany the diagnosis. Shorter psychotic episodes are classed as acute and transient psychotic disorders. Because ICD-11 counts disturbances of self-experience as qualifying symptoms, while DSM-5 counts only hallucinations and delusions, the two systems can classify the same patient differently.

Prodromal and residual phases

Schizophrenia is often preceded by a prodrome lasting from days to years. Typical changes include social withdrawal, a decline in school or work performance, reduced hygiene, suspiciousness, sleep problems, and brief perceptual distortions. These signs are nonspecific and overlap with anxiety, depressive, and personality disorders as well as with substance use. Researchers therefore use terms such as clinical high risk (CHR) for this state. Structured interviews such as the SIPS and the CAARMS help clinicians rate attenuated psychotic symptoms and functional decline. Most people who meet high-risk criteria never develop a psychotic disorder, with estimates of transition to psychosis around 20 per cent in the literature, so neither DSM-5-TR nor ICD-11 treats the prodrome as schizophrenia. Clinicians emphasise monitoring, supportive and cognitive interventions, and family work, and they generally avoid antipsychotic prevention because the benefit-risk balance is unclear. The residual phase, which follows an active episode, is assessed in the same way: the clinician looks for persisting negative or attenuated symptoms while avoiding a label that could stigmatise someone whose course is uncertain.

Differential diagnosis

Several conditions must be separated from schizophrenia. In bipolar disorder with psychotic features, delusions or hallucinations occur mainly during major mood episodes. Schizoaffective disorder requires a major mood episode during most of the illness, while psychotic symptoms must persist for at least two weeks without one. Substance-induced psychosis, linked to cannabis, stimulants, hallucinogens, or withdrawal, can closely mimic the disorder. Clinicians typically wait to see whether symptoms continue for about a month after intoxication or withdrawal ends. Psychosis due to medical conditions is a further important category. It includes endocrine and metabolic disturbances, delirium, neurological disease, and autoimmune encephalitis, which can produce psychosis, catatonia, and cognitive change that look like a primary psychotic disorder. Laboratory and neurological workups are therefore part of the assessment.

Categorical versus dimensional approaches

Both DSM and ICD use categories: a person either meets the threshold or does not. Critics argue that symptoms vary continuously across the population, that the boundary with bipolar disorder and schizoaffective disorder is arbitrary, and that a single label obscures differences in symptom profile and severity. Dimensional and symptom-based models instead rate the severity of positive, negative, cognitive, and mood domains, using instruments such as the Positive and Negative Syndrome Scale. ICD-11 adds some of this flexibility through symptom qualifiers and severity and functional descriptors.

Agreement between clinicians remains a concern. Operational criteria improved reliability compared with the earlier, looser diagnoses of the mid-twentieth century, but ratings still vary. Negative symptoms and disorganized speech depend on observation and judgment, and negative symptoms can be confused with depression or with the side effects of medication. Field trials, including national ICD-11 trials that tested the reliability of the new guidelines, are used to address these problems, but the question of how consistently different clinicians apply the same criteria is still open.

Course, Onset, and Outcome

Schizophrenia most often becomes apparent in late adolescence or early adulthood. Incidence peaks in the twenties, with male rates roughly two and a half times female rates in one cohort estimate. Incidence estimates for schizophrenia-spectrum disorders peak at ages 20 to 29, at about 4.15 per 10,000 person-years among males and 1.71 among females. Male sex is linked to earlier onset, but that gender difference disappears among people with a family history or cannabis use. Women show a second, flatter rise around menopause, and the overall lifetime risk appears similar for the two sexes. Schizophrenia is a disorder of all ages, and epidemiological studies that stop at age 45 to 55 understate later onset.

Childhood and adolescent precursors are usually identified only in retrospect. Lower premorbid adjustment, meaning weaker school performance, developmental delay and few peer relationships, often precedes illness. A gradual onset during this period can be mistaken for ordinary adolescent difficulty or substance use, which delays diagnosis. The most common definition of early-onset schizophrenia uses an onset before age 18. Early-onset cases appear to follow a harsher course. In a systematic review of 21 studies, only 15.4% of patients in early-onset studies had a "good" outcome, compared with 19.6% in mixed-onset studies.

The course is variable. Schizophrenia was long regarded as a chronic disorder with steady deterioration, but some recent studies have shown a better prognosis. In a long follow-up of about 11 years after first admission, the number of relapses ranged from none to 29, with a mean of about three. Relapses involving positive symptoms were the most frequent but also the shortest, averaging about two months. Patterns therefore include episodic courses with recovery between episodes, persistent symptoms with continuous disability, and gradual decline. A moderate number of people do remit and stay well, and some of them need no maintenance medication. Strict recovery criteria are far more demanding: one clinical study requiring two years of sustained remission of positive and negative symptoms with adequate social and vocational functioning found a recovery rate of 14% within the first five years. The first two years of illness are informative, since the course in those years was often predictive of the long-term course.

Several factors are associated with outcome, though their independent weight is debated. The duration of untreated psychosis (DUP) is among the most studied. A meta-analysis of first-episode cohorts found a modest association between DUP and outcome, which supports trials that test reducing DUP. Patients with a long DUP were significantly less likely to achieve remission. That association was not explained by premorbid adjustment, although other studies have found weak or no effects, and one cohort reported that outcome was significantly worse when DUP exceeded one to three months. Premorbid functioning carries its own signal: in a prospective study of 423 patients, impaired pre-morbid development was independently associated with more negative symptoms and poorer social outcome. Age at onset is also contested. A meta-analysis found that younger age at onset was correlated with more hospitalizations, more negative symptoms, more relapses, poorer social or occupational functioning and poorer global outcome, although the correlations were small. Another review concluded that there was no support for age at onset influencing the outcomes studied. Social circumstances matter as well: in one long-term study, early social intervention was also related to a better outcome.

Mortality is a central part of the picture. Reviews estimate that life expectancy in patients may be 15–20 years shorter than in the general population, with the longevity gap increasing over time. Premature death is mainly due to preventable natural causes, such as cardiovascular disease, infections, respiratory tract diseases and cancer, alongside suicide, homicide and accidents. Physical illness accounts for most of the excess: cardiovascular events are the commonest cause of death in people with psychotic disorders. Metabolic side effects of antipsychotic medication, unhealthy lifestyles, limited access to physical healthcare and irregular treatment are all proposed contributors, although their relative contributions are not firmly established. In one cohort, violent deaths, including suicides and accidents, accounted for 17.07% of all mortality. Estimates of the gap vary between studies and countries, so the figures above should be read as approximate ranges rather than fixed values.

Epidemiology and Risk Factors

Prevalence worldwide

Schizophrenia is uncommon but widespread. One review places its lifetime occurrence at about 0.3–0.7% of the general population, which corresponds to roughly 21 million people worldwide as of 2020. A more specific synthesis gives a lifetime prevalence of around 0.50% and a lifetime morbid risk of around 0.72%; the morbid-risk measure also counts people who have died by the time of assessment. The round figure of "about 1%" that appears in many trial protocols and clinical summaries is an older shorthand. A recent meta-analysis notes that studies on the lifetime prevalence of schizophrenia in the general population have not been updated or limited to a single country or region, which is one reason estimates vary.

Variation has several sources. Estimates differ by study design, with higher lifetime rates in cohort studies than in cross-sectional studies, higher rates in Europe than in North America, and higher rates in lower-quality studies. Prevalence also depends on how cases are ascertained, and on whether the survey relies on clinical interviews, records or screening instruments. Early cross-national comparisons were central to this debate. The WHO-coordinated International Pilot Study of Schizophrenia in the late 1960s and early 1970s compared rates and outcomes across diverse centres, and its findings helped establish the view that the disorder appears in every society studied, though course and outcome differed. Later WHO-linked diagnostic work, including the field trials for ICD-10, shaped the criteria used in these comparisons.

Sex, urbanicity and migration

Incidence is not evenly distributed. A systematic review of incidence studies found that the distribution of rates was significantly higher in males compared to females, with a median male/female rate ratio of 1.40. A later meta-analysis of psychotic disorders reported a higher rate in men for non-affective psychoses, while incidence was lower in men than in women for affective psychoses, a pattern that underlines how diagnostic boundaries affect the numbers.

Urban upbringing and migration show similar gradients. Studies conducted in urban areas, as opposed to mixed urban-rural catchment areas, generated significantly higher rate distributions. A Danish national cohort found that the risk linked with residing in a highly urbanized environment was at least twice as high as that associated with living in a very sparsely populated rural environment. The migrant gradient is the largest of the three. In one review, the migrant/native-born rate ratio median was 4.6, and the excess was particularly pronounced among black immigrant communities in some analyses.

These patterns raise methodological questions. Researchers have proposed toxic exposures, diet, infections, stress, or an artefact due to selective migration as explanations for urban-rural differences, and a study of exposure timing suggested that continuous or repeated exposures during upbringing affected schizophrenia risk. Because the urbanicity effect is hard to isolate from social and genetic factors, the difficulty in isolating specific environmental risk elements underlying urbanicity effects on schizophrenia incidence exemplifies a serious methodological challenge. Notably, the same review found that overall quality, methods related to case finding, diagnostic confirmation and criteria, and the use of age-standardization were not associated with significantly different rate distributions.

Environmental risk factors

Several environmental exposures have been studied repeatedly. The list includes obstetric complications, infections, winter or spring birth, migration, urban living, childhood adversity, and cannabis use. The evidence is uneven. Of the numerous studies of environmental risk factors for schizophrenia, some have yielded reproducible findings, and the research on these exposures has been far less consistent for bipolar disorder.

Adolescent cannabis use is among the best-supported later exposures. Studies following people from birth to adulthood have identified cannabis use in childhood or adolescence as a likely risk factor. Evidence suggests it may act partly by advancing onset: one first-episode study found that male cannabis users were a mean of 6.9 years younger at illness onset than male nonusers, which fits the view that cannabis can trigger illness in people who are already predisposed.

Prenatal infection and nutrition form another group. Several viruses are known to damage fetal brain development, and a 1988 investigation in Finland suggested a higher incidence of schizophrenia among cohorts that were in utero during the second trimester of gestation. Other work points to a remarkable concordance between the occurrence of schizophrenia and congenital neural defects following severe famine in early gestation. Reviews generally list maternal infection, prenatal malnutrition and birth complications together as associated factors.

Obstetric complications are the most debated. Recognized complications include maternal bleeding, diabetes, rhesus incompatibility, pre-eclampsia and abnormal fetal growth and development. However, most of these obstetric associations are small, and other potential influencing factors weren't controlled for, so some apparent effects may reflect infection or other confounders. Childhood adversity is also linked to the disorder, and the clinical literature commonly reports that different trauma types correlate with social and academic premorbid adjustment from childhood to late adolescence.

Familial clustering

Risk is strongly concentrated in families. Older figures compiled from the literature suggest that among first-degree relatives, the risk has been reported to vary from 6% in parents, to 10% in siblings, and to 13% in children of schizophrenic individuals, and that the risk rises when both parents are affected. These numbers are many times higher than the general population rate of roughly 0.5–1%. Yet family history, although the best established risk factor for the disease, may account for a limited proportion of the population occurrence of schizophrenia. Most cases arise in people without an affected first-degree relative, which is why researchers increasingly study how genetic liability interacts with early environmental exposures.

Genetic and Neurodevelopmental Foundations

Heritability and what the estimates mean

Twin and family research has long pointed to a strong inherited component. A 2003 meta-analysis of twin studies gave a heritability of 81% (95% confidence interval, 73%-90%), and it estimated that shared environmental influences accounted for a joint estimate of 11%. These figures are model-based. Heritability describes how much of the variation in liability across a population is associated with genetic differences under the environments studied, not how much of one person's illness genes cause. The method also rests on assumptions. Critics have questioned the doubling of the difference between identical- and fraternal-twin concordance (Falconer's formula), and the diagnostic category itself. The concordance data show the same limit from another angle: identical twins share essentially all their DNA, yet monozygotic concordance is around 40%–50%, so genes alone do not determine the outcome. Relative risk is also much higher among close relatives than in the wider population, with around 10% in first degree relatives, compared with a lifetime risk of about 1%.

Common variants and polygenic architecture

Genome-wide association studies (GWAS) have found the genetic signal to be widely distributed. The first large studies identified 108 potential loci in 36,989 patients versus 113,075 controls, and later collaborations raised the count to 287 in over 76,755 cases vs. 243,649 controls. Each variant carries a tiny effect, and the signal is spread across very many sites. Some analyses suggest that thousands of common alleles of very small effect contribute to risk. Summing these variants into a polygenic risk score explains only a small share of case–control differences; one recent estimate puts it at around 7.7% of the variance in schizophrenia case-control status. Most of the associated sites lie in noncoding DNA, which suggests that they act through regulatory mechanisms rather than by altering protein sequences directly. Rare variants, including those in coding genes, tend to have larger effects, with odds ratios typically ∼2–60 compared with about ≤1.1 for common alleles.

22q11.2 deletion and other copy-number variants

The most important single genomic lesion is the copy-number variant at 22q11.2. The deletion is the most common human deletion syndrome with an estimated prevalence of 1 in 4000 live births. Carriers face a 20–25-fold risk of developing schizophrenia compared to individuals from the general population, and about a quarter of adults with the deletion develop the illness. The deletion covers dozens of genes, including COMT, ZDHHC8, DGCR8, and PRODH, which have been studied as candidate susceptibility genes. The deletion explains only a small fraction of cases in the general population, since carriers form a small group. Its clinical profile also overlaps with other neurodevelopmental conditions, including learning difficulties, autism spectrum disorder (ASD), cognitive deficits and early language delays ... attention deficit disorder (ADHD). This overlap is one reason researchers consider a shared neurodevelopmental pathway, rather than a schizophrenia-specific one, to be involved. Whole-genome work has proposed that the deletion acts as a threshold-lowering first hit for schizophrenia risk, with additional rare variants shaping who crosses the threshold.

The neurodevelopmental hypothesis

Since Daniel Weinberger's 1987 argument, it has been proposed that schizophrenia reflects abnormal brain development that begins well before the first psychotic episode, possibly during prenatal life or during adolescent remodelling of cortical circuits. Structural imaging supports the idea in group-level terms. Meta-analyses report slightly enlarged lateral ventricles and reduced grey matter, including thinning of parts of the cerebral cortex. These differences are small and overlap substantially with healthy controls, so they cannot be used diagnostically. It is also difficult to tell whether they precede illness or result from it, from antipsychotic treatment, or from illness duration and lifestyle.

Gene–environment interaction

Genetic liability is unlikely to act alone. The diathesis–stress framework, developed in the 1970s, holds that inherited vulnerability becomes clinically relevant when combined with adverse experiences. A well-known Finnish adoption study found that adoptees with a higher genetic liability were more likely to develop psychosis when raised in disturbed family environments. Environmental factors discussed elsewhere in this entry, such as urban upbringing, cannabis use, obstetric complications and childhood adversity, may therefore modify how genetic risk is expressed. Because the common-variant signal is so diffuse, a gene–environment interaction model is often considered a better fit for the data than a model in which genes and environment contribute independently.

Neurochemical and Neurobiological Hypotheses

The dopamine hypothesis

The dopamine hypothesis came largely from pharmacology. Two observations anchored its classical form: dopamine agonists can induce schizophrenia-like symptoms, and antipsychotic drugs act as dopamine antagonists. The classical version located the problem in subcortical circuits, where psychotic symptoms were associated with dopaminergic hyperactivity, especially increased activity of D2 receptors.

The model was later refined into a two-sided account. Subcortical mesolimbic projections were proposed to be overactive, producing D2 hyperstimulation and positive symptoms, while mesocortical projections to the prefrontal cortex were proposed to be underactive, producing D1 hypostimulation and negative and cognitive symptoms. A deficiency in mesocortical dopamine function might translate into disinhibition of mesolimbic dopamine activity. Dopamine is also carried through nigrostriatal and tuberoinfundibular routes, which account for motor side effects and raised prolactin during antipsychotic treatment.

The hypothesis has clear limits. Imaging showed that a dopamine excess could arise from heavier presynaptic release or from greater postsynaptic receptor density or sensitivity. A PET meta-analysis found no abnormality in drug-free patients; reduced D2/3 receptor availability appeared only in patients who were taking medication, which raises the possibility that part of the signal reflects treatment rather than illness. Dopamine alone does not fully explain the disorder, and newer work highlights glutamate dysfunction, neurodevelopmental factors, and aberrant salience processing.

Glutamate and NMDA receptor hypofunction

Interest in glutamate grew from clinical observations. Psychotic symptoms were precipitated in patients with schizophrenia who were exposed to PCP or ketamine, and in controlled studies, low-dose ketamine given to healthy volunteers produced mild psychosis along with negative and cognitive symptoms that resemble the wider clinical picture. In one double-blind study of 15 healthy men, ketamine infusions produced robust, dose-dependent impairment in verbal declarative memory.

At the molecular level, both drugs act on the NMDA receptor's channel region, which reduces its function. Postmortem work has reported lower levels of the NR1 subunit in prefrontal cortex, though findings for AMPA receptors are less consistent. The model has complications. In rodents, acute systemic ketamine resulted in a paradoxical increase in extracellular frontal glutamate as well as of dopamine. One proposed explanation is that NMDA receptors are mainly blocked on inhibitory GABA interneurons, which disinhibits cortical glutamate neurons, although this remains a hypothesis. Moreover, PCP and ketamine do not function exclusively as NMDA receptor antagonists in the brain. Blockade in animals also reproduces the loss of parvalbumin-containing cells, one of the most compelling findings in the postmortem schizophrenia brain.

Serotonergic hypotheses

The serotonin hypothesis predates the dopamine model. Following Gaddum's demonstration in 1953 that LSD, a hallucinogenic drug, had affinity for serotonin receptors, several lines of evidence suggested a role for serotonin in the pathophysiology of schizophrenia. The idea was complicated by pharmacology, since LSD is a full or partial agonist rather than an antagonist at many 5-HT receptors.

Interest revived with clozapine and later atypical antipsychotics, which act at 5-HT2A receptors. The ratio of 5-HT2A to D2 affinities distinguishes between typical and atypical antipsychotics better than any other known pharmacologic feature. Atypical drugs are thought to block cortical 5-HT2A receptors, and because 5-HT2A receptors are located presynaptically on dopamine terminals in the nigrostriatal and mesocortical pathways, atypical antipsychotics augment dopamine release in these regions. Human imaging results depend on the radioligand used: 5-HT2A receptor density was decreased when quantified with one tracer but increased when evaluated with a tritiated LSD tracer.

Cholinergic and muscarinic hypotheses

Cholinergic theories propose that reduced acetylcholine signaling, particularly at muscarinic receptors in cortex and hippocampus, contributes to cognitive and negative symptoms. Some studies have reported altered muscarinic receptor binding, and the high rate of tobacco smoking among patients has been discussed as possible self-medication through nicotinic receptors. Muscarinic agents are now under clinical investigation, and their development is discussed in the pharmacological section.

Immune and inflammatory hypotheses

Immune hypotheses rest on the finding that a subset of patients show raised circulating or cerebrospinal levels of inflammatory signaling molecules such as cytokines. Some studies have also described activated microglia in brain tissue. These results are inconsistent across studies, and it remains unclear whether inflammation is a cause, a consequence, or simply a marker of illness in a subgroup of patients. The link to maternal infection during pregnancy, discussed in the neurodevelopmental section, is one reason these ideas remain under study.

Pharmacological Treatment

First-generation antipsychotics

The first generation of antipsychotic drugs, developed in the 1950s, includes chlorpromazine and haloperidol. First-generation antipsychotics (FGAs) were developed in the 1950s. Their main therapeutic action comes from blocking D2 dopamine receptors. That same blockade reaches the nigrostriatal pathway, which controls movement, so it also produces the motor side effects known as extrapyramidal symptoms. These include parkinsonism, akathisia, acute dystonia and tardive dyskinesia. The pooled prevalence of antipsychotic-induced parkinsonism, akathisia, and TD were 20%, 11%, and 7%, respectively. Tardive dyskinesia is a chronic condition of involuntary movements, most often of the mouth, tongue and face, and most cases of TD are caused by long-term use of antipsychotic drugs. Its annual incidence is roughly 3 to 5 percent of treated patients, and it can be higher in older adults. Because these effects can persist after the drug is stopped, clinicians now aim to use the lowest effective dose.

Second-generation antipsychotics

Second-generation (atypical) agents were largely introduced in the 1980s and 1990s. Second generation antipsychotic drugs possess a lessened likelihood of causing TD but have other adverse effects such as weight gain and metabolic disturbances. The metabolic burden includes metabolic side effects (e.g., weight gain, insulin resistance), along with dyslipidaemia and a higher cardiometabolic risk. Prolactin effects differ by agent. Risperidone and paliperidone commonly raise prolactin, which can cause breast enlargement, galactorrhoea and sexual dysfunction, whereas aripiprazole tends to have little effect on prolactin. Olanzapine and clozapine are more associated with weight gain. Choosing among these drugs therefore involves balancing symptom control, the patient's metabolic and movement risks, comorbid conditions and personal preference. An individualized treatment approach needs to consider current symptoms, comorbid conditions, past therapeutic response, and adverse effects, as well as patient choice and expectations. Large comparative trials such as CATIE and CUTLASS have not found significant differences in Abnormal Involuntary Movement Scale (AIMS) scores between patients taking first- or second-generation antipsychotics.

Clozapine

Clozapine remains the most effective option for treatment-resistant schizophrenia, usually defined as persistent symptoms despite adequate trials of several antipsychotics. Numerous comparative studies between clozapine and other antipsychotics have reported superior efficacy of clozapine in treatment-resistant illness. It was first marketed in Europe in 1971, a few years later, clozapine was removed from the market after its use was shown to be associated with agranulocytosis, a severe drop in white blood cells, following deaths reported in Finland. A seminal study by Kane et al in 1988 demonstrated its superior efficacy in treatment-resistant schizophrenia and led to the reintroduction of clozapine. Clozapine also appears to lower all-cause mortality, including suicide, in people with schizophrenia.

Its rare but serious haematological risk requires routine blood testing. The rates of clozapine induced neutropenia (CIN) and agranulocytosis (CIA) are 3.8 and 0.9%, and the risk of clozapine-induced agranulocytosis is mostly confined to the first year of treatment. In the United States, the FDA's revised monitoring program now relies on absolute neutrophil count rather than white blood cell count. For patients in the general population, clozapine treatment should be interrupted if neutropenia is suspected and the ANC drops below 1000 cells/µL. Critics argue that strict monitoring has contributed to under-prescribing, and some guidelines are being reviewed in that light.

Long-acting injectable formulations

Long-acting injectable (LAI) antipsychotics, including depot forms of haloperidol and fluphenazine and newer products such as paliperidone palmitate and long-acting aripiprazole, release medication over weeks or months. This reduces the dependence on daily oral adherence, which is a major reason for relapse. Meta-analyses and observational studies generally report lower relapse and rehospitalisation rates with LAIs than with oral drugs, although the benefit is most consistent among patients with a history of poor adherence. Injection-related burdens, the need for clinic visits and the irreversibility of some side effects remain practical concerns.

Xanomeline–trospium (Cobenfy)

Cobenfy pairs two muscarinic agents. Xanomeline has agonist activity at M1 and M4 muscarinic acetylcholine receptors in the CNS. Trospium chloride, a muscarinic antagonist, does not cross the BBB and its primary role is to help mitigate the peripheral side effects associated with muscarinic agonism. The drug was approved by the FDA on September 26, 2024, and it is the first antipsychotic drug approved to treat schizophrenia by targeting the cholinergic receptors rather than the dopamine/serotonin receptors. Approval was based on the phase III EMERGENT-2 and EMERGENT-3 trials. In both, Cobenfy met its primary endpoint, demonstrating statistically significant reductions of schizophrenia symptoms. Its most frequently reported adverse effects are gastrointestinal, such as nausea, vomiting, dyspepsia and constipation, and the label lists contraindications including urinary retention and narrow-angle glaucoma. Because it does not act directly on dopamine D2 receptors, it is expected to avoid some of the metabolic and movement effects of older drugs, but long-term data and direct comparisons are still limited.

Psychosocial and Service-Based Care

Antipsychotic medication is usually combined with psychological, family-based and vocational support. The evidence for these approaches is strongest for relapse prevention and for functional recovery, and the effects are generally modest and depend on how well services are delivered.

Cognitive behavioural therapy for psychosis

Cognitive behavioural therapy for psychosis (CBTp) is a structured talking therapy that helps people examine distressing beliefs and unusual experiences, understand how symptoms affect them, and develop coping strategies. Its main goals are to reduce distress and improve functioning with symptoms that persist, rather than to remove every symptom. Across major reviews, the effect of CBTp on overall symptom severity is modest, with standardised effect sizes ranging between 0.13 and 0.49, and national guidance such as that of the UK's National Institute for Care and Health Excellence still recommends it as a psychological treatment for psychosis.

An individual-participant-data analysis of 14 RCTs (with a combined sample of 898 randomised participants) found that CBTp produced greater reduction in PANSS general symptoms and PANSS total symptoms post treatment, compared to other psychological interventions, but the advantage did not appear for positive and negative symptoms of psychosis considered separately. The same analysis suggested that baseline symptom severity did not predict who benefited, while delivering enough therapy sessions did matter (investing in sufficient dosage of CBTp is important). CBT-informed treatment has also been studied in people at high clinical risk who are not taking antipsychotics; one meta-analysis reported that the relative risk of developing psychosis was reduced by more than 50% for those receiving CBT at every time point, although these trials are few and small.

Family interventions and psychoeducation

Family work ranges from basic psychoeducation, which covers the illness, its treatments and early warning signs of relapse, to more intensive programmes that also aim to construct an alliance with relatives who care for the person with schizophrenia, reduce adverse family atmosphere, and enhance the capacity of relatives to anticipate and solve problems. Relapse is the outcome where the evidence is most consistent. An early meta-analysis found that the relapse rate can be reduced by 20 percent if relatives of schizophrenia patients are included in the treatment. A later network meta-analysis of 90 clinical trials with more than 10,000 patients found that 9 of the 11 interventions were superior to regular care at reducing patient relapse at 12 months, and the simplest model, family psychoeducation, was associated with the lowest relapse rates (the simplest approach—basic family psychoeducation). Durability differs by model: one network analysis found that the benefit of psychoeducation alone was not observed at follow-up observations longer than 12 months, whereas another reported that almost all interventions were effective in preventing relapse even at follow-up observations longer than 12 months. Caregiver burden and distress are commonly addressed in these programmes too, but outcomes in this domain are measured less consistently.

Supported employment and cognitive remediation

Unemployment is a central source of disability in schizophrenia, and vocational support is one of the most studied responses. The individual placement and supported (IPS) model of supported employment is the most empirically validated model of vocational rehabilitation for persons with schizophrenia or another serious mental illness. Its key feature is sequencing: SE/IPS is 'place-and-treat/train' whereas TAU is 'train/treat-then-place', meaning job placement begins alongside clinical care rather than after stabilisation. In early psychosis, an assessor-blinded trial in British Columbia found that use of the Individual Placement and Support strategy further increased employment, despite the high baseline rates. For people who are still in school, IPS has been adapted for education as well, and a randomised trial in the United States tested it against a workplace-skills module during the first 18 months after a first episode (evaluated in a rigorous 18-month randomized controlled trial the efficacy of an enhanced vocational intervention).

Cognitive remediation is a set of structured exercises intended to improve attention, working memory and problem-solving, usually linked to real-world goals such as work or independent living. Its functional benefits are more variable than its effects on laboratory tests, and it is most often combined with vocational or skills-based programmes.

Coordinated specialty care for early psychosis

Coordinated specialty care (CSC) is a team-based model for people in the first few years after a first episode. A typical programme, usually lasting about two years, combines case management, low-dose medication, psychoeducation, family support and help with school or work. The rationale is that intervening early may shorten the period of untreated illness and protect functioning. Trials of this model, including the US RAISE-ETP and NAVIGATE studies and the earlier Danish OPUS trial, reported better engagement with treatment and, on several measures, better symptom and functional outcomes than usual community care. Whether these gains persist after programme support ends is less settled, and results vary across sites and outcome measures.

Community mental health teams, assertive outreach and housing

Most people with schizophrenia are followed by community mental health teams, which coordinate medication, psychological support and social care. For people who frequently disengage or are repeatedly admitted, assertive community treatment (ACT) provides multidisciplinary care delivered in the person's own environment, with small caseloads and outreach that continues when appointments are missed. Its clearest benefits are for reducing hospital use and improving continuity, with less consistent effects on symptoms.

Stable housing is a precondition for many of these services to work, since unstable accommodation makes it harder to take medication, attend appointments and sustain employment. Supported housing models, including Housing First, have strong evidence for keeping people housed, although their effects on clinical outcomes are more mixed. Continuity of care across hospital, community and housing settings depends on discharge planning and shared information, and gaps at these transitions remain a common source of relapse and readmission.

Comorbidity, Mortality, and Social Consequences

Physical illness and the mortality gap

Excess death is one of the most consistent findings in schizophrenia research. Patients with schizophrenia have two-fold to three-fold higher mortality rates compared with the general population, corresponding to a 10-25-year reduction in life expectancy. Other estimates are wider, placing the gap at 13 to 30 years, so the figure depends on the populations and methods used. Although the mortality rate from suicide is high, natural causes of death account for a greater part of the reduction in life expectancy. The main natural causes are cardiovascular disease, cancer, diabetes mellitus, and other natural causes, and these deaths are linked to diagnostic delay and under-treatment as well as to modifiable risk factors.

Several mechanisms are usually cited. Reviews point to unhealthy diets, excessive smoking and alcohol use, and lack of exercise, to the metabolic side effects of some antipsychotics, and to physical illnesses that are common, but diagnosed late and treated insufficiently. Weight gain and insulin resistance matter in particular: weight gain, insulin resistance, metabolic syndrome and diabetes mellitus are frequent in patients with schizophrenia, and may worsen the risk of cardiovascular diseases. Smoking is a major contributor. Estimates suggest that smoking accounts for about half of the life expectancy gap in women and one-third of the gap in men. Because tobacco use is so common in this group, cessation is one of the more concrete targets for reducing the gap.

Substance use and suicide

Substance use disorders are a frequent companion of schizophrenia. In two national cohorts from Finland and Sweden covering more than 45,000 people, substance use disorders (SUD) were highly prevalent (at least one in four). Comorbidity carries a measurable cost: any SUD comorbidity in schizophrenia was associated with 50% to 100% increase in hospitalization and mortality risks compared to schizophrenia patients without SUD. The excess mortality is concentrated in suicides and other external causes. Substances also make the illness harder to manage, since they can worsen psychotic symptoms, reduce adherence to treatment, and interact with prescribed drugs.

Suicide is a central concern. Suicide is the leading cause of unnatural death among people with schizophrenia. Reviews put the lifetime suicide risk at roughly 5%, and up to 40% of this excess premature mortality can be attributed to suicide and unnatural deaths. Risk is higher with number of prior suicide attempts, depressive symptoms, active hallucinations and delusions, and the presence of insight, and with comorbid substance misuse. The only consistently protective factor identified is delivery of and adherence to effective treatment. Treating co-occurring conditions together is difficult, because services are often split and these comorbidities, which often remain underdiagnosed and untreated. The same logic applies to physical illness, which is often overlooked in clinical practice.

Social costs

The economic burden extends well beyond health care. A 2013 US estimate put the total annual excess societal burden of schizophrenia in the US at $155.7 billion, with the largest components tied to unemployment and caregiver productivity loss. A later analysis for 2024 reached $366.8 billion, with indirect costs making up most of the total. Employment is among the most affected areas: individuals with schizophrenia also experience greater unemployment, underemployment, and work productivity loss compared to the general population. In a US veterans cohort, the risk of unemployment and of homelessness were 5.4 and 4.5 times higher among veterans with versus without schizophrenia.

Homelessness and criminal justice contact are closely linked to relapse. Among veterans, those who had a prior relapse showed higher rates of homelessness (homelessness (38.9% vs 23.7%)) than those without. Estimates of the share of homeless people with the disorder vary; one meta-analysis reported 8% to 18% in the American homeless population. Contact with the justice system is also common: in one study, 46% of participants reported at least one interaction with the criminal justice system each year, with 67% of them reported being a victim of crime. Lower educational attainment and reduced earning capacity are also documented, though they are harder to quantify.

Stigma, self-stigma, and coercion

Public stigma and self-stigma, the internalization of negative stereotypes, can lead to shame, lower self-esteem, and reluctance to seek help. People may delay contact with services or leave treatment early, which can prolong untreated illness and raise the risk of crisis. Stigma also shapes how families and employers respond, which adds to social isolation.

Coercion raises separate concerns. Involuntary admission, seclusion, restraint, and forced medication are used in some systems, and they raise questions about autonomy and dignity. The UN Convention on the Rights of Persons with Disabilities holds that a disability must not justify deprivation of liberty, and this has led to debate over involuntary psychiatric detention. Advocates call for reducing coercive practices and strengthening informed, shared decision-making, while clinicians often weigh these principles against the immediate risks of suicide and self-neglect.

Controversies and Open Questions

Is schizophrenia one disorder?

The division Kraepelin drew between dementia praecox and manic-depressive illness still shapes psychiatric nosology, but genetic and clinical data have blurred it. The genetic correlation between schizophrenia and bipolar disorder is roughly 0.7, and it is stronger for bipolar I than for bipolar II. This overlap is too large to be explained by diagnostic misclassification or assortative mating. Some researchers take this as evidence that the two conditions share a biological substrate. Others point out that the overlap is imperfect and that a genetic factor separating them still exists, so some biological validity remains in keeping them apart. Symptom-level studies add complexity. In people with schizophrenia, manic symptoms appear to track the burden of bipolar risk variants more closely than liability to schizophrenia itself, which suggests that the diagnostic boundary may not follow biological lines. Network-level analyses of genetic risk have been read in both directions, and the question remains open. Polygenic architecture, pleiotropy, and the lumping of psychotic subtypes in large genetic consortia all make it hard to say whether the category is a natural kind or a convenient cluster of syndromes. The same problem affects genetics research, which depends on how cases are defined, and diagnosis more generally.

The limits of the dopamine model

All licensed antipsychotics block dopamine D2 receptors at clinical doses, and a threshold level of blockade appears necessary for antipsychotic effect. Yet blockade alone is not sufficient: some patients improve little even when receptor occupancy is high. Dopamine-based accounts also struggle to explain treatment resistance, negative symptoms, and cognitive impairment, which is why glutamatergic, cholinergic, and neurodevelopmental explanations have gained ground. Imaging studies have produced inconsistent results. A PET meta-analysis found a modest rise in striatal dopamine synthesis in medication-free patients, but no reliably replicated abnormality in those already taking drugs. Biomarkers that could guide diagnosis or the choice of treatment are therefore still a research goal rather than clinical tools. Candidates include dopamine imaging, transporter measures, EEG and structural MRI signatures, polygenic risk scores, and machine-learning classifiers built on multimodal data. Most of these have been tested in small samples with heterogeneous patients, and many findings have not been replicated, a problem that broader reproducibility concerns in psychiatry make more acute.

Long-term antipsychotic use

The main tension is between relapse prevention and adverse effects. Meta-analyses consistently show that dose reduction or discontinuation raises relapse risk. In one meta-analysis of randomized trials, relapse was roughly twice as likely after reduction as after maintenance. The English RADAR trial found that severe relapse occurred in about 25% of people whose medication was reduced, compared with about 13% of those who continued, although most participants in both groups did not relapse. Dose-response analyses suggest that little additional protection is gained above a moderate dose, while risk rises steeply at low doses. Critics argue that some relapses after withdrawal reflect the natural course of the illness rather than drug withdrawal, and a 2026 preprint analysing paliperidone discontinuation trials reported two distinct relapse trajectories that did not clearly differ by treatment status. Metabolic effects, movement disorders such as tardive dyskinesia, and subjective burden weigh against long maintenance, and the decision is usually framed as a matter of individual risk and informed-consent rather than a fixed rule.

Overdiagnosis, migration, and cross-cultural variation

Higher rates of diagnosis among some ethnic and migrant groups, notably people of Black Caribbean and African-origin background in parts of Europe, have been reported repeatedly. The explanations offered include true differences in incidence linked to social adversity and urban exposure, clinician bias in assessment, greater use of coercive or emergency routes into care, and differences in how distress is described and interpreted. Each explanation carries methodological problems, and separating them requires careful control for confounding and clear case definitions. Cross-cultural research has also shown that the content of hallucinations and delusions is shaped by religion, language, and local belief systems, and that outcomes can be better in some low- and middle-income settings than in high-income ones. Whether diagnostic criteria capture the same condition across cultures is therefore disputed, and cultural formulation has been added to standard assessment tools to address this.

Non-response and new mechanisms

Up to about 30% of patients meet the definition of treatment-resistant schizophrenia, usually after adequate trials of at least two antipsychotics, and clozapine remains the only agent with clear evidence for this group. Several newer approaches have produced mixed results. Glycine transporter inhibitors and other glutamate-modulating compounds have, for the most part, not delivered consistent benefit in late-stage trials, and trace amine and muscarinic agents have also met with mixed outcomes. The muscarinic agent xanomeline–trospium was approved in 2024, but subsequent adjunctive trials have been less encouraging, which makes its place in treatment still under evaluation. Research is now testing inflammation and immune signalling in the subset of patients with raised cytokines, synaptic pruning and neuroplasticity, and the stratification of patients by genetic or biological profile in the hope that trials will target the right people. Why a substantial proportion of patients remain unresponsive to all current drugs, and whether that group represents a distinct condition, is among the most pressing unanswered questions in the field.

References

1. Kraepelinian dichotomyen.wikipedia.org
2. Dementia praecoxen.wikipedia.org
3. Dementia praecoxgpnotebook.com
4. Eugen Bleuleren.wikipedia.org
5. Psychiatry's contribution to the public stereotype of schizophrenia: Historical considerationsonlinelibrary.wiley.com
6. The birth of schizophrenia or a very modern Bleuler: a close reading of Eugen Bleuler's 'Die Prognose der Dementia praecox' and a re-consideration of his contribution to psychiatry - PubMedpubmed.ncbi.nlm.nih.gov
7. First rank symptoms of schizophrenia: their nature and originresearchgate.net
8. A two-factor structure of first rank symptoms in patients with a psychotic disorder - ScienceDirectsciencedirect.com
9. History of schizophreniaen.wikipedia.org
10. The Name “Schizophrenia” Is Heard Worldwidepsychiatrictimes.com
11. Being Bleuler: The Second Century of Schizophrenia - Robert M. Kaplan, 2008journals.sagepub.com
12. Schneider's first-rank symptoms: history and modern relevance — Fridafridaneuro.com
13. Methods of treatment of schizophreniaimage-ppubs.uspto.gov
14. Salts of piperazine compounds as D3/D2 antagonistsimage-ppubs.uspto.gov
15. Negative symptoms of schizophrenia: Clinical features, relevance to real world functioning and specificity versus other CNS disorders - ScienceDirectsciencedirect.com
16. Primary and Secondary Negative Symptoms in Schizophreniancbi.nlm.nih.gov
17. Catatonia-like behavior and immune activation: a crosstalk between psychopathology and pathology in schizophreniancbi.nlm.nih.gov
18. Full article: Cognitive deficits and functional outcome in schizophreniatandfonline.com
19. Cognitive Symptoms of Schizophrenia: Types and Treatmentspsychcentral.com
20. Associations Between Cognitive Function, Schizophrenic Symptoms, and Functional Outcome in Early-onset Schizophrenia With and Without a Familial Burden of Psychosis - PubMedpubmed.ncbi.nlm.nih.gov
21. Treatment of schizophrenia with catatonic symptoms: A narrative review - ScienceDirectsciencedirect.com
22. Catatonic Schizophrenia: Symptoms and Treatment — Talkspacetalkspace.com
23. Lorazepam-Resistant Catatonia in an Antipsychotic-Naïve 24-Year-Old with Psychotic Symptomsncbi.nlm.nih.gov
24. Catatonic Schizophrenia: What It Is, Symptoms, & More I Psych Centralpsychcentral.com
25. Catatonic schizophrenia: Symptoms, causes, and moremedicalnewstoday.com
26. Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art - ScienceDirectsciencedirect.com
27. COGNITIVE DEFICIT IN SCHIZOPHRENIA: AN OVERVIEWpsychiatria-danubina.com
28. Schizophrenia: An Overview - PMC - NIHpmc.ncbi.nlm.nih.gov
29. An organization‐ and category‐level comparison of diagnostic requirements for mental disorders in ICD‐11 and DSM‐5 - PMCpmc.ncbi.nlm.nih.gov
30. Schizophrenia in ICD-11: diagnosis, symptoms and key changes from ICD-10icd-diagnostica.com
31. Schizophrenia and catatonia: from ICD-10 to ICD-11 - PMCpmc.ncbi.nlm.nih.gov
32. Psychosis and Related Disorders in International... : Indian Journal of Social Psychiatryjournals.lww.com
33. The Italian ICD-11 field trial: clinical utility of diagnostic guidelines for schizophrenia and related disordersncbi.nlm.nih.gov
34. Evaluating and Treating the Prodromal Stage of Schizophreniacdr.lib.unc.edu
35. Understanding suicidality in adolescents and young adults at clinical high risk for psychosis: a narrative review on risk factors and clinical insightsncbi.nlm.nih.gov
36. DSM-5 criteria for schizophrenia, explained plainly — Fridafridaneuro.com
37. Prodromal Symptoms of Schizophrenia: Understanding and Addressing Challengespsychiatrictimes.com
38. What Is the Prodromal Phase of Schizophrenia?choosingtherapy.com
39. F128. THE AGE OF ONSET OF SCHIZOPHRENIA SPECTRUM DISORDERSncbi.nlm.nih.gov
40. From Onset and Prodromal Stage to a Life-Long Course of Schizophrenia and Its Symptom Dimensions: How Sex, Age, and Other Risk Factors Influence Incidence and Course of Illnessncbi.nlm.nih.gov
41. A systematic review of the long-term outcome of early onset schizophreniancbi.nlm.nih.gov
42. Prognosis of schizophreniaen.wikipedia.org
43. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review - PubMedpubmed.ncbi.nlm.nih.gov
44. Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort - ScienceDirectsciencedirect.com
45. The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosiscambridge.org
46. Age at onset and the outcomes of schizophrenia: A systematic review and meta‐analysis - Immonen - 2017 - Early Intervention in Psychiatry - Wiley Online Libraryonlinelibrary.wiley.com
47. Mortality in Schizophrenia-Spectrum Disorders: Recent Advances in Understanding and Management - PMCpmc.ncbi.nlm.nih.gov
48. Mortality in Schizophrenia-Spectrum Disorders: Recent Advances in Understanding and Managementncbi.nlm.nih.gov
49. What is behind the 17-year life expectancy gap between individuals with schizophrenia and the general population?nature.com
50. Predictors of outcome in early-onset psychosis: a systematic reviewnature.com
51. Similarities and Differences in Associations between Duration of Untreated Psychosis (DUP) and Demographic, Premorbid, and Symptom Severity Measures in Two Samples of First-Episode Psychosis Patients from Mexico and the United Statesncbi.nlm.nih.gov
52. Parsing the sizable life expectancy gap for people with schizophreniamanagedhealthcareexecutive.com
53. Epidemiology of schizophreniaen.wikipedia.org
54. Worldwide prevalencelibrary.neura.edu.au
55. Global lifetime prevalence of schizophrenia: A systematic review and meta-analysisnature.com
56. (PDF) A systematic review of the incidence of schizophrenia: The distribution of rates and the influence of sex, urbanicity, migrant status and methodologyresearchgate.net
57. A systematic review and meta-analysis of the incidence of psychotic disorders: the distribution of rates and the influence of gender, urbanicity, immigration and socio-economic levelcambridge.org
58. Urban-Rural Differences in Schizophrenia Risk: Multilevel Survival Analyses of Individual- and Neighborhood-Level Indicators, Urbanicity and Population Density in a Danish National Cohort Studyacademic.oup.com
59. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodologylink.springer.com
60. Urbanization and traffic related exposures as risk factors for Schizophreniancbi.nlm.nih.gov
61. Spatial gene-by-environment mapping for schizophrenia reveals locale of upbringing effects beyond urban-rural differencesbiorxiv.org
62. Environmental Risk Factors for Schizophrenia and Bipolar Disorder and Their Relationship to Genetic Risk: Current Knowledge and Future Directionsncbi.nlm.nih.gov
63. What causes schizophrenia? What we know, don’t know and suspect |…neura.edu.au
64. Full article: Environmental risk factors for psychosistandfonline.com
65. Prenatal Risk Factors in Schizophreniapsychiatrictimes.com
66. Factors Moderating the Relationship Between Childhood Trauma and Premorbid Adjustment in First-Episode Schizophreniancbi.nlm.nih.gov
67. Neuregulin-1 transgenic mouse and methods of useimage-ppubs.uspto.gov
68. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology - PMCpmc.ncbi.nlm.nih.gov
69. Schizophrenia as a Complex Trait: Evidence From a Meta-analysis of Twin Studiesjamanetwork.com
70. Despite What You’ve Heard, “Schizophrenia” Is Not “80% Heritable” - Mad In Americamadinamerica.com
71. Schizophrenia: a classic battle ground of nature versus nurture debate - ScienceDirectsciencedirect.com
72. Common polygenic variation contributes to risk of schizophrenia that overlaps with bipolar disorder - PMCpmc.ncbi.nlm.nih.gov
73. Genetic Variants from Large Cohorts and Familial Studies Implicate Common Mechanisms in Schizophreniadoi.org
74. Genetic architecture of schizophrenia: a review of major advancementscambridge.org
75. Frontiersinfrontiersin.org
76. Exome arrays capture polygenic rare variant contributions to schizophreniancbi.nlm.nih.gov
77. miRNA-mediated risk for schizophrenia in 22q11.2 deletion syndromencbi.nlm.nih.gov
78. 22q11.2 deletion syndrome and schizophreniaacademic.oup.com
79. Whole-Genome Sequencing Suggests Schizophrenia Risk Mechanisms in Humans with 22q11.2 Deletion Syndromencbi.nlm.nih.gov
80. Schizophrenia Risk Mediated by microRNA Target Genes Overlapped by Genome-Wide Rare Copy Number Variation in 22q11.2 Deletion Syndromencbi.nlm.nih.gov
81. Dopamine Hypothesis of Schizophrenia - an overviewsciencedirect.com
82. Neurobiology of Dopamine in Schizophrenia - ScienceDirectsciencedirect.com
83. Dopamine Hypothesis of Schizophrenia: Neurobiological Insightspsychscenehub.com
84. Glutamatergic dysfunction in Schizophreniancbi.nlm.nih.gov
85. Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis - ScienceDirectsciencedirect.com
86. Glutamatergic dysfunction in Schizophrenianature.com
87. Frontiersfrontiersin.org
88. Is the Acute NMDA Receptor Hypofunction a Valid Model of Schizophrenia?academic.oup.com
89. Serotonin 5-HT2 Receptors in Schizophrenia: A PET Study Using [18F]Setoperone in Neuroleptic-Naive Patients and Normal Subjectspsychiatryonline.org
90. The Role of Serotonin in Schizophrenia - ACNPacnp.org
91. New approaches to the management of schizophrenia: focus on aberrant hdovepress.com
92. Opposite alterations of 5­HT2A receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profilenature.com
93. Resolving the heterogeneity of dopamine subsystems dysfunction in schizophrenia: a PET meta-analysisnature.com
94. Frontiersfrontiersin.org
95. Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosisnature.com
96. Full article: What value do NMDA receptor antagonist models of schizophrenia have for novel drug discovery?tandfonline.com
97. Psychedelics and schizophrenia - ScienceDirectsciencedirect.com
98. Serotonergic hallucinogens as translational models relevant to schizophreniaacademic.oup.com
99. Reporting Frequency of Antipsychotics‐Induced Tardive Dyskinesia and Other Extrapyramidal Symptoms: Analysis Based on a Spontaneous Reporting System Database in Japanncbi.nlm.nih.gov
100. Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studiesjournals.plos.org
101. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereofimage-ppubs.uspto.gov
102. Antipsychotics - Knowledge @ AMBOSSamboss.com
103. (PDF) Extrapyramidal Effects of First and Second Generation Antipsychotics: A Reviewresearchgate.net
104. Reducing Involuntary Movements in Participants With Tardive Dyskinesiacdn.clinicaltrials.gov
105. Reduction in Absolute Neutrophil Counts in Patient on Clozapine Infected with COVID-19ncbi.nlm.nih.gov
106. Frequency of neutropenia over time in patients on clozapinemedrxiv.org
107. Clozapine rechallenge and initiation despite neutropenia- a practical, step-by-step guidebmcpsychiatry.biomedcentral.com
108. Management of clozapine-associated neutropeniacambridge.org
109. Risk of neutropenia prompts new monitoring for antipsychotic drugmanagedhealthcareexecutive.com
110. Xanomeline and Trospium Chloride (Cobenfy®) FDA approved September 2024smchealth.org
111. Cobenfy (xanomeline-trospium)wmjonline.org
112. Cobenfy (xanomeline and trospium chloride) FDA Approval History - Drugs.comdrugs.com
113. Cobenfy: A New Mechanism of Action for the Treatment of Schizophreniamedrac.web.unc.edu
114. PureTech Health plc - Form 20-F - FY2024sec.gov
115. BRISTOL MYERS SQUIBB CO - Form 10-K - FY2024sec.gov
116. Extrapyramidal motor side-effects of first- andsecond-generation antipsychotic drugscambridge.org
117. Treatment effect modifiers of cognitive behaviour therapy in people with psychosis: an individual participant data meta-analysis of RCTsdoi.org
118. Meta-analysis and Meta-regression of Cognitive Behavioral Therapy for Psychosis (CBTp) Across Time: The Effectiveness of CBTp has Improved for Delusionsacademic.oup.com
119. Efficacy and Moderators of Cognitive Behavioural Therapy for Psychosis Versus Other Psychological Interventions: An Individual-Participant Data Meta-Analysis - PubMedpubmed.ncbi.nlm.nih.gov
120. Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysiscambridge.org
121. Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis - The Lancet Psychiatrythelancet.com
122. The effect of family interventions on relapse and rehospitalization in schizophrenia--a meta-analysis - PubMedpubmed.ncbi.nlm.nih.gov
123. Family Interventions Benefit People With Schizophreniapsychiatryonline.org
124. Evidence-based psychosocial interventions in schizophrenia: a critical review - PMCpmc.ncbi.nlm.nih.gov
125. Supported employment for persons with serious mental illness: Current status and future directions - ScienceDirectsciencedirect.com
126. Supported employment: Meta-analysis and review of randomized controlled trials of individual placement and supportncbi.nlm.nih.gov
127. “Individual Placement and Support” boosts employment for early psychosis clients, even when baseline rates are high - Erickson - 2021 - Early Intervention in Psychiatry - Wiley Online Libraryonlinelibrary.wiley.com
128. Enhancing return to work or school after a first episode of schizophrenia: the UCLA RCT of Individual Placement and Support and Workplace Fundamentals Module training - PubMedpubmed.ncbi.nlm.nih.gov
129. Individual placement and support: History, current status, and future directions - Drake - 2023 - Psychiatry and Clinical Neurosciences Reports - Wiley Online Libraryonlinelibrary.wiley.com
130. Life expectancy and cardiovascular mortality in persons with schizophrenia - PubMedpubmed.ncbi.nlm.nih.gov
131. core.ac.ukcore.ac.uk
132. Life Expectancy and Cardiovascular Mortality in Persons with Schizophreniaresearchgate.net
133. [Smoking and schizophrenia: epidemiological and clinical features] - PubMedpubmed.ncbi.nlm.nih.gov
134. Cigarette Smoking and Life Expectancy in Schizophreniapsychiatrictimes.com
135. Morbidity and mortality in schizophrenia with comorbid substance use disorders - PMCpmc.ncbi.nlm.nih.gov
136. Substance use and self-poisoning in schizophrenia: 11-year findings from a national clinical survey of suicide in mental health patients in the UK - PubMedpubmed.ncbi.nlm.nih.gov
137. Suicide and schizophrenia: a systematic review of rates and risk factors - PMCpmc.ncbi.nlm.nih.gov
138. Facts & Figures - Schizophrenia & Psychosis Action Alliancesczaction.org
139. Economic Cost of Schizophrenia in US Tops $350 Billionmedscape.com
140. 2021 Schizophrenia & Psychosis Action Alliancesczaction.org
141. (PDF) Unemployment, homelessness, and other societal outcomes in patients with schizophrenia: a real-world retrospective cohort study of the United States Veterans Health Administration database: Societal burden of schizophrenia among US veteransresearchgate.net
142. Unemployment, Homelessness, and Other Societal Outcomes Among US Veterans With Schizophrenia Relapse: A Retrospective Cohort Studypsychiatrist.com
143. Management of schizophrenia and comorbid substance use disorders: expert review and guidance - PMCpmc.ncbi.nlm.nih.gov
144. Unraveling the Association Between Schizophrenia and Substance Use Disorder-Predictors, Mechanisms and Treatment Modifications: A Systematic Reviewncbi.nlm.nih.gov
145. Genomic findings in schizophrenia and their implicationsnature.com
146. Genetic overlap between autism, schizophrenia and bipolar disorder - PMCpmc.ncbi.nlm.nih.gov
147. Network localization of genetic risk for schizophrenia and bipolar disorder - PMCpmc.ncbi.nlm.nih.gov
148. Genetic Studies of Schizophrenia and Bipolar Disorderpsychiatryonline.org
149. The common genetic liability between schizophrenia and bipolar disorder: A review.link.springer.com
150. Association of schizophrenia polygenic risk score with manic and depressive psychosis in bipolar disorderncbi.nlm.nih.gov
151. The Dopamine Hypothesis of Schizophrenia: Version III—The Final Common Pathway - PMCpmc.ncbi.nlm.nih.gov
152. The nature of dopamine dysfunction in schizophrenia and what this means for treatment - PMCpmc.ncbi.nlm.nih.gov
153. Treatment-resistant schizophrenia: pathophysiology and the role of neuroimaging and therapeuticscambridge.org
154. Antipsychotic treatment in schizophrenia: balancing relapse prevention and functional recoverynature.com
155. The Course of Relapse Following Antipsychotic Discontinuation in Schizophrenia: A Test of the Antipsychotic Withdrawal Syndrome Hypothesis of Relapsemedrxiv.org
156. Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial - The Lancet Psychiatrythelancet.com
157. Helping people to discontinue antipsychotics: if, when and hownature.com